CMS RBCS · Tests · Molecular Testing

COVID Specific codes

8 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Molecular Testing K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 300.24M services · est. ▲ 71.7% YoY · 14.69M FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 153.28M observed fee-for-service services

See the national market for K1034 → ranked groups · states · 12-yr trend

HCPCS · Molecular Testing U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 2.80M services · est. ▼ 80.6% YoY · 636,315 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 1.48M observed fee-for-service services

See the national market for U0005 → ranked groups · states · 12-yr trend

HCPCS · Molecular Testing U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 2.45M services · est. ▼ 80.1% YoY · 584,402 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 1.29M observed fee-for-service services

See the national market for U0003 → ranked groups · states · 12-yr trend

HCPCS · Molecular Testing U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 583,053 services · est. ▼ 84.5% YoY · 89,116 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 311,338 observed fee-for-service services

See the national market for U0004 → ranked groups · states · 12-yr trend

HCPCS · Molecular Testing U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 186,428 services · est. ▼ 5.1% YoY · 45,678 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 89,238 observed fee-for-service services

See the national market for U0002 → ranked groups · states · 12-yr trend

HCPCS · Molecular Testing U0001 Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 491 services · est. ▼ 64.9% YoY · 211 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 245 observed fee-for-service services

See the national market for U0001 → ranked groups · states · 12-yr trend

2 more CPT-coded procedures — shown with a trial or subscription, under AMA licensing.